PTL-202, Pacific’s lead pipeline product for idiopathic pulmonary fibrosis, has completed preclinical and Phase I clinical testing, with the combination drug’s first clinical test demonstrating encouraging results that may result in patients requiring much lower doses.
Results from preclinical tests on animal models show the combined treatment’s superior efficacy in addressing inflammation and fibrotic activity, compared to treatment with the individual components. At present, Pacific is awaiting patent approval in the United States, and in other countries, which follows PTL-202’s approval in Europe in 2014.
- Disorders & Diseases
- Public Health
- Products & Treatment
- Department Management